Phase 2 trial of EYP-1901 in wet AMD meets all endpoints

Key Takeaways

• EYP-1901, a 6-month sustained-delivery treatment for wet AMD, demonstrated noninferior change in best corrected visual acuity compared with aflibercept control.
• EyePoint is preparing to initiate a phase 3 pivotal trial in the second half of 2024.

EyePoint Pharmaceuticals is developing a treatment for wet age-related macular degeneration (AMD) that combines EyePoint’s proprietary sustained delivery technology and the drug vorolanib, which blocks the receptors for vascular endothelial growth factor (VEGF), a signaling protein produced by cells that stimulates the formation of new blood vessels and is implicated in the pathology of wet AMD. The investigational product was evaluated as a 6-month treatment for wet AMD in the phase 2 DAVIO 2 trial.

According to a company press release, the phase 2 DAVIO 2 trial of EYP-1901 met all primary and secondary endpoints in patients with wet AMD. Both doses of EYP-1901 demonstrated noninferior change in best corrected visual acuity compared with aflibercept control (an injectable anti-VEGF therapy). Secondary endpoints that were met included safety, change in central subfield thickness (an anatomical marker commonly used in clinical trials), the number of eyes that remained free of supplemental anti-VEGF therapy and the number of aflibercept injections in each group. EyePoint plans to initiate a phase 3 pivotal trial of EYP-1901 in wet AMD in the second half of 2024.

Source: Healio Ocular Surgery News, December 5, 2023; see source article